Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab

Table 1 Univariate analysis for PFS and OS

				PFS	OS
Perfusion parameter			Threshold	[P-value]	[P-value]
Atlas-defined perfusion parameters
	Pre-Treatment
		Hypervascular Volume	2.35 cc	0.0027**	0.0654
		Hypervascular Volume Fraction	9%	0.8236	0.0546
		Mean Z-Score Value	0.575	0.3521	0.1771
	Post-Treatment
		Hypervascular Volume	0.14 cc	0.0025**	0.0304*
		Hypervascular Volume Fraction	8.9%	0.1320	0.0242
		Mean Z-Score Value	0.5	0.1023	0.0091**
	Change
		Change in Volume	1 cc	0.2061	0.0563
		Percentage Change in Volume	80%	0.0672	0.0483*
		Change in Mean Z-Score	0.08	0.7764	0.0497*
Traditional perfusion parameters
Mean rCBV [a.u.]
	Pre-Treatment
		Mean Standardized CBV	3800	0.9704	0.0872
	Post-Treatment
		Mean Standardized CBV	2500	0.374	0.1499
	Change
		Change in Mean Standardized CBV	120	0.1209	0.3475
Max rCBV [a.u.]
	Pre-Treatment
		Max Standardized CBV	17000	0.7228	0.0555
	Post-Treatment
		Max Standardized CBV	14200	0.2022	0.0823
	Change
		Change in Max Standardized CBV	0	0.0316*	0.6288

ISSN: 1470-7330